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ABSTRACT 
Hepatocellular carcinoma (HCC) is the most common primary 
malignant tumour of the liver, and is globally considered to be a 
major causes of cancer-associated mortality. The early diagnosis of 
HCC improves overall survival through the application of suitable 
treatment options. This article presents some of the techniques for 
the surveillance of HCC like ultrasonography and the use of tumour 
biomarkers such as α-fetoprotein (AFP), DesGamma-Carboxy 
Prothrombin (DCP) and others. Included in the discussion will be 
diagnostic methods like computed tomography (CT), magnetic 
resonance imaging (MRI), contrast enhancement ultrasound (CEUS), 
and fluorodeoxyglucose positron emission tomography hybrid 
with computed tomography (FDG PET/CT). Current molecular 
pathogenesis related to HCC and the molecular steps that determine 
the transition from benign to malignancy are also analysed. The HCC 
stages which depends on the Barcelona Clinic Liver Cancer (BCLC) 
algorithm are also discussed. Finally, this review article discusses 
the present therapeutic and treatment options for HCC such as 
resection, transplantation, or ablation used to treat early stage cancer. 
Also included will be trans-arterial chemoembolization (TACE) and 
Sorafenib for patients with intermediate and advanced-stage cancer, 
respectively.
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to 60% of patients with end-stage liver disease and portends a poor 
prognosis. Recent studies have shown sarcopenia as a novel risk fac-
tor for developing NAFLD. Pathophysiological mechanisms relating 
sarcopenia and NASH may include insulin resistance (IR). There are 
many main risk-factors for HCC and other hepatocarcinogenesis in-
cluding hepatic cirrhosis, chronic inflammations such as HBV, HCV, 
alcohol consumption, cigarette smoking, aflatoxin exposure, NAFLD, 
and autoimmune diseases. HBV patients, unlike HCV patients it can 
immediately develop HCC without going through cirrhosis first. At 
the same time, NAFLD increases the HCC probability and happens 
mainly in patients with metabolic syndrome and obesity[3] which is 
associated with progression to cirrhosis and is rapidly becoming the 
leading indication for liver transplantation. Sarcopenia is defined as 
a progressive and generalized loss of skeletal muscle mass, strength 
and function. It is seen in up to 60% of patients with end-stage liver 
disease and portends a poor prognosis. Recent studies have shown 
sarcopenia is a novel risk factor for developing NAFLD. Pathophysi-
ological mechanisms relating sarcopenia and NASH may include 
insulin resistance (IR and type 2 diabetes[4] provided that all other 
etiologies of liver disease were ruled out, fatty liver was present on 
abdominal ultrasound and alcohol consumption was excluded. Also, 
the human immunodeficiency virus (HIV) is considered a co-risk fac-
tor for HCC development[5,6]. 
THE HCC PROGRESSION
The liver continuously repairs the damaged cells within it. If the liver 
cells are continually forced to repair itself, this raises the chances of 
genetic mistakes or mutation, which potentially leads to development 
of carcinogenesis. 
    In the hepatocytes, the connective tissue surrounding the hepatic 
cells contain different types of cells such as fibroblasts, endothelial 
cells, and macrophages. After the development of a tumor in the 
epithelial cell, the tumor cells spread within the surrounding cells 
and then penetrate the cells and contact the ECM. Thus, the tumor 
cells will produce the tumorigenesis factors like cytokines and 
growth factors such as transforming growth factor beta (TGF-β) and 
platelet-derived growth factor (PDGF). The PDGF stimulates the 
tumor proliferation associated fibroblasts while TGF-β stimulates 
the synthesis of connective tissue. The activated fibroblasts which 
are produced by the different tumorigenesis secretions will produce 
some components which are related to the connective tissue such as 
collagen 1 and 3. Therefore, the TGF-β stimulates to generate the 
matrix metallopeptidase 9 (MMP9) which are symbolized as scissors, 
and the latter would work on the digestion of connective tissue 
components such as collagen fibers[7].
1. The role of hepatocyte growth factor in the development of 
HCC 
Both PDGF and TGF-β co-energize to activate the HSCs[8]. HSC 
works on the development of cancer cells. This occurs by producing 
the cytokines and growth factors to help the cell proliferation for 
cancer cells like hepatocyte growth factor (HGF) which is also 
known as scatter factor, and interleukin-6 (IL-6). 
    HGF binds to the cell membrane receptor of tumor cells activating 
MET which stimulates motility and invasive growth of HCC cells[9]. 
The epithelium experiences higher pressure whenever the density 
of the connective tissue matrix increases. The higher pressure may 
produce morphological changes like those seen in carcinomas. In 
this model, tumor associated fibroblasts produce collagen fibrils as 
a response to TGF-β, with increasing collagen content and stiffness 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is considered as primary carcinoma 
in the liver, and the third vital carcinoma in the world after lung can-
cer and colorectal cancer. It was described as the fifth and seventh 
most common cancer in men and women, respectively[1]. HCC global 
distribution differs depending on the country, for example, African or 
Asian people, the HCC is considered as the most morbidity cancer 
into these countries. There are different risk-factors which increases 
the risk of HCC including hepatic cirrhosis, chronic inflamma-
tions such as Hepatitis B- (HBV), Hepatitis C-virus (HCV), alcohol 
consumption, aflatoxin exposure, non-alcoholic fatty liver disease 
(NAFLD) and autoimmunity cases[1]. 
    The microenvironment is complex system considered to contain 
many components such as stromal cells, extracellular matrix (ECM) 
components (proteoglycans, collagens), hepatic stellate cells (HSC), 
fibroblasts, myofibroblasts and soluble factors, non-cellular compo-
nents (such as cytokines and growth factors). The microenvironment 
is an essential media for epithelial cell transformation, the cell polar-
ity and cell proliferation controlled by this transformation[2] HCC and 
ICC are still deadly cancers worldwide waiting for innovative thera-
peutic options. Growing evidence from the literature highlight the 
critical role of the tumor cell microenvironment in the pathogenesis 
of cancer diseases. Thus, targeting the microenvironment, particularly 
the crosstalk between tumor cells and stromal cells, has emerged as 
a promising therapeutic strategy. This strategy would be particularly 
relevant for liver cancers which frequently develop in a setting of 
chronic inflammation and microenvironment remodeling associated 
with hepatic fibrosis and cirrhosis, such processes in which hepatic 
stellate cells (HSC. The wrong change in the micro-environment 
leads to the formation of cancer by changing the distribution of mo-
lecular biology, histopathology, biochemistry, and genes deformation.
    HCC propagate and starts to be metastasis in different organs of the 
body such as lungs (55%), bone (28%), adrenal glands (11%), lymph 
nodes (53%), and brain (2%). It is considered very rare to affect other 
organs like spleen, duodenum, esophagus, or seminal vesicles. In the 
present work, the risk factors that leads to HCC, tumor progression, 
diagnosis, surveillance, staging, and treatments in HCC are summa-
rized.
EPIDEMIOLOGY, ETIOLOGY AND RISK 
FACTORS 
The rate of incidence of HCC increases with age and it reaches a 
peak at 65 years in European countries, while for populations in East 
Asia and Africa the age of incidence of HCC is much lower. HCC 
is uncommon in patients under 40 years old, and increasing with 
patients aged over 65 years, with the highest probability in patients 
aged over 75 years.
    The HCC malignant progression is related to genetic, lifestyle and 
environmental factors[3] which is associated with progression to cir-
rhosis and is rapidly becoming the leading indication for liver trans-
plantation. Sarcopenia is defined as a progressive and generalized 
loss of skeletal muscle mass, strength and function. It is seen in up 
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of the connective tissue matrix, whereby the regular structure of the 
gland is lost.    
    When HGF connects to c-Met, which is considered one of the 
tyrosine kinase receptors, which are found in endothelial cells, 
hepatocytes, neurons, and epithelial cells which involve the 
epithelial-mesenchymal transition. However, HGF induces the c-Met 
to activate, and stimulate the signalling pathways such as signal 
transducer and activator of transcription, phosphoinositide 3-kinase 
(PI3K), mitogen activated protein kinase (MAPK), and nuclear factor 
kappa-B (NFκB). Thus, c-Met induces the proliferation, survival, 
invasiveness, mobilization, vascular endothelial growth (VEGF-A) 
expression which is released by tumor angiogenesis[10] and epithelial-
mesenchymal transition[11].    
    In addition, the HSC was noticed as a primary cell in tumorigenesis 
associated with the gut system. Therefore, the gut system works 
to stimulate the inflammatory and fibrogenic responses. Thus, the 
HSC activation will produce epiregulin which is used as a mitogenic 
factor for hepatocytes[9]. HSC is involved in tumor formation in late 
stages as in the early stages. It works to produce the factors that 
share to form the prometastatic microenvironment such as epithelial-
mesenchymal cell transition (EMT) in which the epithelial cells lose 
their ability to stick between cells[7]. The HSC also helps to produce 
immune-regulatory cytokines such as monocyte chemoattractant 
protein 1 (MCP1), chemokine ligand 21(CCL21) and CCL 5, 
chemotaxis and activate inflammatory cells.
2. The role of diseases in the development of HCC 
2.1. Liver cirrhosis 
HCC is associated with other liver diseases that increase the risk of 
cancer development and grow in the liver such as liver cirrhosis. 
Where one-third of patients with liver cirrhosis develop their disease 
due to HCC. Liver cirrhosis is associated with other diseases such 
as alcoholic hepatitis, hereditary hemochromatosis, primary biliary 
cirrhosis, alpha-1 antitrypsin (A1AT, A1A, or AAT) deficiency, and 
others[12].
 
2.2. Chronic Inflammations 
The second most common risk factor that is linked with HCC are the 
different inflammations such as HBV and HCV. This is because it is 
involved in the pathogenesis of cancer. Both of these inflammations 
would be developed into chronic or long-lasting. In this case, the 
cells are at a higher risk because of the constant state of infection and 
immune cell attack leading to continuous damage and repair. HBV 
is particularly problematic because of how the virus replicates. HBV 
is a DNA virus that integrates into the hepatocyte’s DNA, which is 
still not completely understood. It is thought to either directly disrupt 
the regulation of cell growth and replication leading to carcinoma or 
cause some indirect effect that later leads to unchecked cell growth 
and replication[13]. Recent studies have identified distinct surface 
markers of cancer stem cell (CSC). HCV acts on cell signalling 
pathways by inhibiting the tumor suppressor genes (P53) and 
suppresses the retinoblastoma protein, which increase the probability 
of carcinogenesis. Moreover, the HCV induces the TGF-β to activate 
the HSCs[5].     
    In addition, the variety of inflammations represent a useful 
prognostic marker for HCC, including fibrinogen, inflammation 
based index (IBI), C-reactive protein (CRP), inflammation based 
score (IBS), Glasgow prognostic score (GPS), and neutrophil to 
lymphocyte ratio (NLR)[14]. NLR is a simple marker of inflammation, 
it provides a good indication of the patient’s overall inflammatory 
status, also it has been used to predict tumor recurrence in HCC 
patients after hepatic resection[15,16] hepatocellular carcinoma (HCC. 
NLR has been related with activate caspase-1, which induce to 
produce the interleukin-18 (IL-18) and interleukin-1β (IL-1β). The 
NLR also plays a key role in cell proliferation, survival and invasion. 
NLR is interested in NF-κB and MAPK for signalling pathways. 
Thus, NLRs share in progression of HCC[15,16].
 
2.3. Aflatoxin B1 exposure 
Another risk factor is Aflatoxin B1 exposure which is considered a 
highly toxic chemical produced by certain Aspergillus molds that 
can be found in specific food when they start to decay like grains, 
peanuts and vegetables. The Aflatoxin B1 is metabolized in the liver. 
Its epoxide can bind to liver cell DNA, resulting in DNA adducts. 
This interaction leads to mutations in the protein p53 (TP53) tumor 
suppressor gene. The p53 gene usually right functioning by stopping 
the formation of tumors by converting the cytochrome P450 into 
8,9-exo-epoxide, thus the DNA damaging would not be happened, 
but if the mutation and dysfunction occurred, the tumor formation 
and carcinogenesis might follow[12].
2.4. Hormone Distribution
The sex differences of androgenic hormones are considered as 
another risk factor. Testosterone accelerates hepato-carcinogenesis, 
while estrogen suppresses the development of liver cancer. Because 
of that, the HCC prevalence in males are higher than that of the 
female while the diagnosis related age in females is more than 
males[12].
3. HCC Biomarkers 
Biomarkers for HCC are associated with variations in metabolism, 
and genetic, epigenetic, and protein levels. Metabolic changes 
play an essential role in determining the different HCC stages. The 
differential metabolites such as glutamine, short/medium chain 
acylcarnitines, pro-inflammatory precursor arachidonic acid level, 
and cyclic adenosine increase the probability of HCC formation[18].
3.1. RNA Biomarkers 
The human genome consists of less than 2% of protein-coding 
genes. More than 90% of the genome is copied to non-coding 
RNA (ncRNA) such as microRNAs (miRNAs), which is related 
to potential disease biomarkers. The miRNAs are considered as 
small non-coding RNA molecules. They contain 22 nucleotides and 
regulates the expression of genes at the post-transcriptional level.The 
miRNAs can be confined found into a vesicle, especially an exosome 
of about 50-100 nm diameter and then excreted to the extracellular 
environment and transferred into recipient cells[19]. The cellular 
miRNAs regulate the different cell activities such as differentiation, 
apoptosis, proliferation and angiogenesis[20].     
    The nucleus contains the miRNAs genes which are similar to the 
proteins. RNA polymerase II is responsible for transcribing DNA 
genes, which produces either a messenger or regulatory RNA. The 
hairpin loop structure of primary miRNA will become the final 
miRNAs by several steps of transcription process. The miRNAs 
are produced by cutting the RNA into the smaller precursors, via 
the microprocessor complex which is formed by protein DGCR8 
getting associated with enzyme Drosha. After that, the miRNAs 
can be exported into the cytoplasm. Thus, the messenger RNA will 
be inactivated in multiple genes. Exportin-5 (XPO5) works as a 
transporter of the precursor miRNAs out of the nucleus through the 
nuclear pores. In the cytoplasm, the miRNAs can be recognized by a 
large RNA protein known as Dicer. The role of Dicer is to cleave the 
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miRNA into short double-stranded molecules, which binds with[21]. 
The release of one strand is occurred, while the strand which remains 
that known as the guide strand will interact with another protein to 
form the RNA that motivate a silencing complex RISC. The RISC 
complex prevents the ribosome subunit from translating into a 
protein, so the gene is silenced. The tumorigenesis development can 
happen in the interaction between non-coding RNAs (lncRNAs), 
mRNAs and miRNAs[1]. 
3.2. Genetic level 
At the genetic level, many mutated genes related to HCC such as 
ubiquitin conjugating enzyme E2 Q1(UBE2Q1), TP53, HOTTIP, 
telomerase reverse transcriptase (TERT), catenin beta 1 (CTNNB1), 
and myelocytomatosis (MYC) were discovered. MYC is considered 
as a regulator gene for the transcription factor that adjusts the 
expression of genes for different kinds of genes in the cancer features 
such as proliferation, survival, metabolism, and self-renewal. Thus, 
inactivation of MYC oncogene leads to tumor regression associated 
with differentiation, apoptosis, and proliferative arrest[20]. The gene 
encoding HOTTIP have also been shown to have a significant 
oncogenic role in HCC, by dysregulation of HOXA genes. 
    Hexokinase is one of the enzymes found only in HCC and not in 
healthy liver cells. There are five hexokinases encoded by different 
genes in the human cells. Hexokinase 2 (HK2) is found in cardiac 
and skeletal muscles, outer mitochondrial membrane and adipose 
tissues and are also found in cancer cells. The HK2 induces the HK4 
or glucokinase (GCK), which is the main hexokinase in HCC[22]. 
Moreover, HK2 induces the glucose transporter 1 (GLUT-1) which 
induce p53, and the PI3K/AKT pathway[13]. 
3.3. Epigenetic level 
Epigenetic alterations, will occur through changes at the gene 
transcription level without changing the DNA sequence. Thus, the 
gene expression level would be altered. The characterized of the 
ncRNAs and the related with HCC were identified by using advanced 
sequencing technologies. The changing of the series of nucleotides 
between 26 to 32 in ncRNAs represents approximately half of HCC 
tumors cases. This change is linked directly to increased proliferation 
rate and leads to improvement in the tumorigenesis properties, and 
that happens through active AKT signaling. At the same time the 
abnormal regulation either via upregulation of miR-21, miR-34a, 
miR-221 and miR-222 or downregulation of miR-122a, miR-145, 
miR-199a and miR-223 leads to HCC. 
    MiR-122 is considered a negative regulator of pyruvate kinase 
isoenzyme M2 (PKM2). PKM2 represents as inhibitor of HCC 
aerobic glycolysis, in vitro cell proliferation, as well as in vivo tumour 
growth and metastasis. Moreover, also the pyruvate kinase can be 
regulated by mineralocorticoid targeting miR-388-3p
[13]. Figure 1 
shows the composition and miRNAs in the HCC-derived exosome. 
3.4. Protein level 
As for proteins, the high-mobility group box protein 1 (HMGB1) is 
one of the nuclear DNA binding protein which binds to chromatin, 
and is found in eukaryotic cells. HMGB1 plays a vital role in HCC 
carcinogenesis invasiveness and progression. The nucleus and 
the cytosol secretes the HMGB1 into the ECM. When HMGB1 
is combined with DNA, it interacts with the different kinds of 
transcription factors such as NF-κB, p53, and TATA-binding proteins. 
In the ECM, the HMGB1 links to many receptors such as glycation 
end products (RAGE), (TLR)-2, TLR-4, TLR-9, and activating renin-
angiotensin system (RAS)-MAP kinase[23] high mobility group box 1 
(HMGB1). 
    Forkhead box protein M1(FOXM1) is another protein which is 
found in HCC and which is encoded by the FOXM1 gene. FOXM1 
is used as a biomarker for prediction of cancer at the early stages. 
It plays an important role in mitotic division, and also affects the 
S and G2/M phases by regulating the expression of G2/M specific 
genes such as cyclin B2, Plk1, CENPF, and Nek2. In addition of 
that, FOXM1 plays an essential role in chromosomal segregation 
maintenance[24]. 
    The control mechanism in the mitotic phase that ensures accurate 
chromosome segregation is the spindle assembly checkpoint (SAC), 
and any defect of SAC leads to tumorigenesis. Aurora kinase A 
(AURKA), is one of the mitotic serine/threonine kinases which 
plays a vital role in mitosis that is related to centrosome duplication 
and separation, maturation, and cytokinesis (function of cell 
proliferation). The dysregulation of AURKA leads to chromosomal 
instability and increases the probability of tumorigenesis such as 
HCC. AURKA promotes tumour proliferation, differentiation, 
metastasis, and induces chemo-sensitivity in HCC[25]. 
    There are other proteins associated with mitotic division such as 
Zwint proteins. Zwint is a complex-centromere protein component 
required for the SAC process; it is involved in kinetochore 
function (disc-shaped protein structure, found at the centromere 
of a chromatid) and growth of the cell. Zwint connects with Zw10 
(another kinetochore protein) to regulate the interaction between 
Zw10 and other kinetochores. Moreover, Zwint is associated with 
chromosome-instability and found in many human malignancies 
and prognosis in primary tumors. Zwint depletion may reduce cell 
proliferation and HCC cell-cycle progression[26]. A centromere-
complex component required for the mitotic spindle checkpoint, has 
been reported to be overexpressed in different human cancers, but it 
has not been studied in human HCC. 
    In addition, many hepatic progenitor cell (HPC) markers include 
Osteopontin, epithelial cell adhesion molecule (EpCAM), neural cell 
adhesion molecule (NCAM), cytokeratin 19 (CK19), Niemann-Pick 
C1-like 1 (NPC1L1), delta- like 1 homolog (DLK1), surface marker 
Vimentin, DNA repair pathway members and TGF-β/Sirtuin have 
been identified as a potential functional biomarkers of HCC[12]. 
DIAGNOSIS OF HCC 
Non-invasive imaging is an important method to detect stages of 
HCC. The basic concept of HCC is to detect peculiar vascular 
perturbation, which occurs through hepatic carcinogenesis. The 
HCC detection is based on contrast enhancement in diagnostic 
modalities like CT and MRI. There are three phases enhancement Figure 1 Composition and miRNAs in the HCC-derived exosome.
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MDCT or MRI without the need for biopsies especially in cirrhotic 
patients or in chronic hepatitis B patients when the vascular pattern 
is distinctive. Moreover, if the vascular pattern is not distinguishing, 
biopsies should be performed. However, the Gd-EOB-DTPA, should 
be completed before any biopsy procedure[31].
2. Contrast-enhanced ultrasound 
The Contrast-enhanced ultrasound (CEUS) has a possibility of risk 
misdiagnosis between HCC and new nodules in cirrhosis especially 
in nodules related to cholangiocarcinoma (CC). The HCC and CC 
follow a pattern by washout at CEUS, and this would reduce the 
accuracy of diagnosis. The washout of CC would happen earlier than 
60 s after the injection, and the washout intensity in the portal phase 
is more remarkable compared with HCC. Thus, HCC can be detected 
by late (> 60 s) washout after contrast injection[27].    
    CEUS has more specificity than CT and MRI for diagnosing the 
difference between CC and HCC within the 10-20 mm nodules, 
while the sensitivity is less than both of CC and HCC. However, the 
highest sensitivity and specificity for CEUS to detect the 20-30 mm 
nodules were noticed[27]. In addition, CEUS can be considered more 
effective in identifying the lesions in cirrhosis. The contrast media 
used in CEUS such as sulfur hexafluoride and octafluoropropane 
combined with a phospholipid shell has a short arterial phase, so the 
liver exploration is not adequate to visualize the deep lesions. The 
problem with CEUS is that the images acquired cannot be reviewed 
once the images are acquired, unlike CT and MRI. CEUS was 
recommended in the lesions - other than HCC - that shown in CT/ 
MRI. Moreover, another contrast media used in the US such as the 
sinusoid - CEUS which used to detect the lesions that have a very 
late washout because using Kupffer phase. However, the combination 
of CEUS and contrast enhanced MRI is recommended for nodules 
between 1 and 2 cm.
3. Value of FDG-PET 
18F-fluorodeoxyglucose positron emission tomography hybrid 
with computed tomography (FDG PET/CT) is a helpful tool used 
in molecular imaging to detect the stages of cancer tissue. In HCC 
patients, the FDG avidity is a tool used as a prognostic indicator of a 
primary and aggressive tumor that get together with tumor recurrence 
and pathological markers[32].    
    HCC is one of the tumors that uptake FDG-PET but not too high. 
11C-choline have been suggested as another tracer other than 18F-FDG 
to detect HCC. However, the results obtained was less than the 
contrast-enhanced CT and MRI. So far, the 18F-FDG-PET uptake can 
be used in the prognosis of HCC, even though it can be associated 
with poor results. The aim of 18F-FDG-PET uptake is that it can 
be used to help select the patients for liver resection (LR) or liver 
transplantation (LT)[11,33].    
    The sensitivity of 18F- FDG PET/CT is less than 70%. Moreover, 
the uptake of 18F-FDG in HCC is highly variable, also the 18F-FDG 
uptake is high in normal liver tissue. Thus, the difference between 
HCC and normal liver tissue looks to be limited. The standardized 
uptake values (SUVs) of HCC associates with the serum AFP are 
considered high.
STAGING OF HCC 
The management and prognosis of HCC follow one classification 
known as the Child-Turcotte-Pugh (CTP) classification, and it de-
pends on tumor burden, patient’s liver function and liver performance 
status. CTP classification is used to understand the HCC staging. 
to visualize the lesions: late arterial phase, portovenous phase, and 
delayed phase.    
    The HCC has a typical hallmark of contrast enhancement because 
the nutrients of HCC are directly coming from the hepatic artery 
while the parenchymal cells derive oxygen and nutrients via the 
portal vein. Thus, the HCC has shown as a hyper-vascularity in the 
late arterial phase, while in the portovenous phase HCC behaves less 
bright because it contains blood free of contrast (washout) and these 
features known as classic feature. HCC diagnosis depends on the 
imaging modality used in detection of tumor size[7].    
    Early detection of HCC would reduce the risk of developing 
carcinogenesis. At this stage, HCC would be demonstrated as 
hypo-vascular because the arterial feeding has not fully developed. 
Lesions of less than 2 cm must be detected because delaying 
diagnosis decreases the treatment efficiency or increases the chance 
of tumor recurrences. The optimum management of nodules with 
diameters of less than 1 cm that shows the HCC model has not yet 
been demonstrated. Thus, the biopsy should be applied whenever 
the technical condition is suitable[27]. However, biopsy has many 
disadvantages; it is not an optimal choice in all cases, it is rather 
expensive, it can cause pain and anxiety, there are sampling errors 
particularly for small lesions, and of course there are bleeding 
complications.
1. HCC diagnosis in CT and MRI 
Previous studies have shown that the sensitivity is higher in MRI 
compared to CT. The sensitivity depends on tumor size; MRI has a 
62% sensitivity while CT has a 48% sensitivity for detecting small 
lesions less than 2 cm versus 95 % in MRI and 92% in CT for 
detecting lesions more than 2 cm. Previous studies have also shown 
that the sensitivity of gadoxetic acid-enhanced MRI is greater than 
multiphasic CT while the specificity is the same, especially for small 
lesions[28]. The big difference in detection was in lesions less than 1 
cm, where the sensitivity of MRI was higher than CT. However, the 
specificity for both modalities was low[29]. 
    In MRI, the HCC shows a hyper-intensity in T2-weighted and 
diffusion-weighted images. The gadoxetic acid or gadobenate 
dimeglumine contrast media used in MRI have a higher sensitivity 
than with extracellular agents[28]. The gadoxetic acid has a unique 
feature in hepatic cells, just 50% of the injection dose is absorbed 
by hepatocytes and excreted by bile ducts, while the other 50% 
is excreted by the kidneys. This feature has a consequence in the 
diagnostic field: one of this, in the late dynamic phase gained 3 
minutes. Thus, in this period the concentration would be combined 
between extracellular and hepatocellular so that the lesion will appear 
as hypo-intensity looks like washout. The second consequence, 
the hypo-intensity lesions seen in the hepatobiliary phase indicates 
a decrease in membrane transporters not related to the washout 
phenomenon. Therefore, the washout or capsule appearance 
of gadoxetic acid contrast can cause the only diagnosis in the 
portovenous phase[30]. A scientist has developed a new contrast media 
that is specifically used in MRI. The gadolinium-ethoxybenzyl-
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA, Primovist or 
Eovist) enhanced MRI detecting the nodules both of HCC and high-
grade dysplastic nodules (HGDNs). The hypointense nodules seen 
in the hepatobiliary phase and not related to HCC is considered as 
a high risk of HCC progression compared with the hyperintense or 
isointense nodules. The image quality would be decreased because 
of the respiratory motion artefact, which is produced in the arterial 
phase. Thus, the lesions through this phase would be missed.    
   Liver nodules, more than 1 cm should be scanned with dynamic 
least one of them is more than 5 cm, while the T4 disease related to 
major vascular invasion[37].
SURVEILLANCE OF HCC
The purpose of surveillance is to reduce the numberof deaths from 
HCC. Thus, diagnosis in the early stages enhances the therapies used 
and leads to improved treatment and is cost-effective. HCC surveil-
lance depends on the tumor growth rate, tumor incidence in the target 
population, final functional status, overall health, and patient’s age[38].
    Ultrasound is one of the most widely used methods for surveillance 
and monitoring of the HCC patients. It can also be used to observe 
other diseases which are developed within the development stage in 
HCC such as ascites, portal hypertension and portal vein thrombo-
sis[39] as confirmed by resection. Case presentation: A 64-year-old 
man was referred to our hospital for suspected HCC. Contrast-en-
hanced computed tomography (CECT. The sensitivity of examination 
reaches 58 to 89% with a specificity of more than 90%. However, 
the US examination has less sensitivity to detect early stage of HCC 
and less effectiveness to detect small tumor lesions because of liver 
echotexture.
    The HCC surveillance can also be detected by CT and MRI. De-
spite the high cost of examination compared with ultrasound, it is 
useful in patients in whom it cannot be achieved by US, especially in 
Many systems can be used to detect the HCC staging such as Bar-
celona Clinic Liver Cancer (BCLC), Japan Integrated staging (JIS), 
Cancer of Liver Italian Program (CLIP) score and American Joint 
Committee on Cancer (AJCC) to estimate the liver dysfunction se-
verity[35] but their performance in outcome prediction is unclear. We 
aimed to investigate 10 currently used liver function models in HCC 
patients undergoing radiofrequency ablation (RFA). However, the 
most widely used staging systems are BCLC and AJCC system.
    The BCLC system classification in both the staging and the treat-
ments methods depending on both the tumor status (number, size, 
N1, M1, and vascular invasion) and liver function (liver function 
preservation, portal hypertension, and bilirubin). Figure 3 shows the 
stage, treatment methods and survival period for HCC which affiliate 
BCLC system.
    According to BCLC system, the first stage of the HCC is very 
early stage (BCLC stage 0) which known as a single tumor less than 
2cm without the vascular invasion and with conserved liver function 
(Child-Pugh A class patient with no any ascites). Early HCC (BCLC 
stage A) can define as the patient who has a single tumor less than 2 
cm or three nodules all of them less than 3 cm with well-preserved 
liver function, and no clinically significant portal hypertension.
    The intermediate HCC (BCLC stage B) can be defined as a multi-
nodular asymptomatic tumor without extrahepatic spread and without 
vascular invasion. Also, the large solitary less than 5 cm with an 
expansive growth undergoes this stage. Moreover, this stage includes 
the patients who have a Child-Pugh A-B with refractory ascites, bac-
terial peritonitis, and encephalopathy. The advanced HCC (BCLC 
stage C) is retained to the patients with cancer symptoms (symptomatic 
tumors), macrovascular invasion, and extrahepatic spread (metasta-
ses). While the final stage (the end-stage of HCC) is represented for 
patients who have a severe tumor related disability, and there is no 
treatment option can be provided in this stage.
    The second widely used system for determining the staging of 
HCC is AJCC, the new 8th edition staging system (Table 1), which 
uses the T classifications. The HCC were categorized as; T1a for the 
solitary tumors less or equal to 2 cm with or without vascular inva-
sion, T1b for the solitary tumors more than 2 cm with or without 
vascular invasion. T2 classified as larger solitary tumors more than 
2cm and less than 5 cm with vascular invasion as well as multifocal 
tumors. Next classified is T3 where contains multifocal tumors at 
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Table 1 HCC Staging System by AJCC 8th Edition[37].
Primary tumour (T) Regional lymph nodes (N) Distant metastases (M)
T1a Solitary tumour < 2 cm with/without vascular invasion Nx: Regional lymph nodes cannot be assessed
M0: No distant 
metastasis
T1b Solitary tumour > 2 cm without vascular invasion N0: No regional lymph node metastasis
M1: Distant 
metastasis
T2 Solitary tumour > 2 cm with vascular invasion or multifocal tumours, none > 5 cm Multifocal
N1: Regional lymph node 
metastasis
T3 Multifocal tumours at least one of which is > 5 cm
T4
Single tumour or multifocal tumours of any size involving a major branch of the portal 
vein or hepatic vein or tumour(s) with direct invasion of adjacent organs other than the 
gallbladder or with perforation of visceral peritoneum
Stage
Stage IA T1a N0 M0
Stage IB T1b N0 M0
Stage II T2 N0 M0
Stage IIIA T3 N0 M0
Stage IIIB T4 N0 M0
Stage IVA Any T N1 M0
Stage IVB Any T Any N M1
Figure 2 Diagnostic algorithm for suspected HCC.MDCT, MRI, US, and 
biopsy [31].
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Figure 3 BCLC staging system for HCC. Prognostic stage, treatment methods and survival period [36].
Figure 4 HCC treatment related to stages.
patients who are obese or have intestinal gas. Moreover, many non-
invasive liver function models can be used to assess the hepatic injury 
severity due to the HCC development such as the albumin-bilirubin 
(ALBI) grade, platelet-albumin-bilirubin (PALBI) grade, and albu-
min-to-alkaline phosphatase ratio (AAPR). Another model can also 
be used to assess the liver dysfunction in HCC know as model for 
an end-stage liver disease (MELD) which depends on prothrombin, 
creatinine and serum bilirubin[35] but their performance in outcome 
prediction is unclear. We aimed to investigate 10 currently used liver 
function models in HCC patients undergoing radiofrequency ablation 
(RFA).
    In addition, the BALAD score is another model that can be used 
for surveillance, prediction of the survival, and recurrence of HCC. 
BALAD consists of 5 serum biomarkers, the Bilirubin and Albu-
min is used to assess the remnant liver function, while the other 
three biomarkers related to serum tumor biomarkers are: AFP, Des-
Gamma-Carboxy Prothrombin (DCP), and Lens culinaris agglutinin-
reactive AFP (AFP-L3)[40]. AFP is considered as an oncofetal protein 
also known as alpha-fetoglobulin. A raised level of AFP is a sign of 
increasing HCC risk factor, but the raised level of AFP is not an accu-
rate indicator in all cases. Only a small percentage (10-20%) of early 
tumor stage can be detected by increasing AFP serum levels. Also, 
AFP is considered as a widely HCC biomarker proposed for predic-
tion of HCC recurrence[40,41] it is necessary to establish a compre-
hensive panel of HCC biomarkers related to tumour behaviour and 
cancer prognosis. Resected HCCs from 251 patients were stained for 
hepatic progenitor cell (HPC). These tumor markers have a low sen-
sitivity for detection early stage of HCC. However, the combination 
of two or more markers would enchase the early stage diagnostic[31].
    The European Association for the Study of the Liver (EASL) rec-
ommended that the US and AFP should be used every six months 
as a surveillance system. They were represented as a reasonable 
choice and a suitable period to see the HCC development especially 
for early-stage and shorter survival[43]. Moreover, the Japan Society 
of Hepatology (JSH) have recommended the surveillance should be 
combining between US and tumor markers at least three markers 
including AFP, DCP, and AFP-L3. US have a high sensitivity and 
specificity comparing with AFP level and can be detected by the le-
sion with a small diameter which reaches to 1 cm. The US examina-
tion also recommended for the patient who have HCV and cirrhosis 
within 3 months[5]. CT and MRI with multiphasic contrast-enhanced 
are bespoken to assess the response after treatment.
HCC TREATMENT AND MANAGEMENT
The HCC treatment depends on the hepatic function and planning of 
therapy that classified according to the specific system is known as 
Child-Pugh system. The Child-Pugh system is grading of chronic liv-
er disease and given information about liver severity. The system was 
developed in 1973 and depends on five factors: thrombin time, albu-
min, total bilirubin, Ascites and hepatic encephalopathy. Prothrombin 
time and albumin are tests of the liver sympathetic functions; a fail-
ing liver cannot produce enough clotting factors in albumin. Total 
bilirubin reflects the liver’s ability to eliminate bilirubin via the bile 
duct. Ascites and encephalopathy are symptoms resulting in liver 
failure. Ascites is an accumulation of the fluid in the peritoneal cav-
ity caused by increased pressure in the portal vein due to cirrhosis. 
Hepatic encephalopathy is a change in mental status caused by the 
build-up ammonia and other waste products that are usually removed 
by the liver. For Child-Pugh score system, patients are scored based 
on the values of their prothrombin time which are usually expressed 
as INR. The total bilirubin, the albumin concentration and then the 
severity of the ascites and encephalopathy. The score range from 5 
to 15 with 15 being the worst (A 5-6 score, well compensated; B 7-9 
score, significant functional compromise; and C 10-15 score, decom-
pensated)[44]. The type of treatment used in HCC depends on many 
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Figure 5 The surgical treatment planning [31].
pre-treatment evaluations factors such as tumor number, tumor size, 
tumor location, the presence of liver disease, major vascular invasion 
and lymph node metastasis.
1. Early stage treatment 
In the early HCC stage, the curative treatment is applied and it can 
be achieved by LR, LT, radiofrequency ablation (RFA) or radiation 
segmentectomy (RS). The LR used to treat the very early stage with 
single nodule less than 2cm, while LT and RFA early stage with some 
nodules less than 3 and the size less than 3 cm. The LR still unsatisfy-
ing results with more than 70% of recurrent patient cancer. However, 
the advantage of surgical resection can demonstrate the early recur-
rence of the cancer tissue by pathology including the microvascular 
invasion. The survival for a long-term is achieved through surgical 
treatment. However, less than 20% of patients can do the surgical 
operations. Therefore, the non-surgical patients undergo to different 
treatment strategies such as RFA, percutaneous ethanol injection, se-
lective internal radiation therapy (SIRT), stereotactic body radiation 
therapy (SBRT), laser induced thermotherapy (LITT), electromag-
netic tracked laparoscopic ultrasound (ELUS) and chemoemboliza-
tion[32].
    The LT can be applied for HCC patients, which have a single tu-
mor less than 5 cm in diameter or the patient who have three nodules 
each one not more than 3 cm in diameter and without major vascular 
invasion (Milan criteria). It can also be applied for patients with a 
high-risk recurrence of cancer cells which found in the LR[10]. How-
ever, the recurrence of tumor in LT reaches to 20%, and this would 
have happened because the inability of preoperative radiological pro-
cedures to determine the tumor numbers and sizes and prediction of 
tumor’s aggressiveness. 
    Also, the RFA of lesions is less than 2 cm and have been demon-
strated to complete ablation in more than 90% of cases and a recur-
rence rate of less than 1%[45]. The RFA can also be applied for HCC 
with a diameter less than 7 cm. However, the multiple ablations 
tumor, the combination of both therapies may work better than using 
each therapy alone and may help people with liver cancer live longer.
    Stereotactic body radiotherapy (SBRT) is used when the LT, LR 
and RFA not suitable in HCC treatment. The aim of this strategy is 
to focus on damage to cancer cells while keeping healthy cells intact.
SBRT is applied in patients with lesions which is located near to the 
central portal area and close to hepatic vessels and near to the biliary 
system. SBRT is primarily used in the patients with small HCC who 
cannot undergo to surgery, RFA, or transplantation[52].
3. Advanced stage
Sorafenib is considered as the first oral multi-kinase inhibitor, its ef-
fect on serine/ threonine and receptor tyrosine kinases and used to 
treat both of tumor cells and tumor vasculature. Through the signal 
transduction process, the signals from the outside and within the 
cell are transferred to the nucleus by using protein known as RAS 
protein. Thus, the signal transduction pathways respond to cellular 
proliferation, angiogenesis, and cellular death. The RAS pathway 
contains MAPK protein kinase cascade. The latter consists of three 
kinases RAF, MEK and extracellular signal- regulated kinase (ERK). 
Through the growth regulating cascade, all of these kinases helps to 
transmit the signals from the membrane to the cell nucleus[34]. In the 
nucleus, the transcription factors are activated which regulate genes 
such as cell differentiation and growth genes where the regulation 
is controlled in normal cells. In the cancer cells, the transmit mes-
sages are continuously deregulated the cellular proliferation, and 
this occurred through overexpression of upstream and downstream 
effectors such as RAS or RAF. The sorafenib is applied to targets the 
RAF pathway so that the cell proliferation can be controlled. The 
cell growth factors such as VEGFR and PDGF are activated by the 
angiogenic process hence the blood cell growth, tube formation, and 
migration would increase. The sorafenib exerts an anti-angiogenic. 
Thus, the growth of blood vessels is prevented, and that would hap-
pen through the blockade of the receptor tyrosine kinases VEGFR2 
to VEGFR3, PDGFR, RET, KIT, and TGF-β and their associated 
signalling cascade including the RAF, MAKK, ERK pathway. There-
fore, the tumor cell proliferation and tumor angiogenesis would be 
controlled[53,54]. Sorafenib is used to treat the advanced stage of the 
HCC. However, sorafenib has some limitations such as low response 
rate, complex mechanism following acquired resistance, little surviv-
al advantage, and high-level of individual response heterogeneity[55].
    Another oral multi-kinase inhibitor is Regorafenib (commercial 
name known as Stivarga) and Nivolumab which is not considered as 
an oral multi-kinase inhibitor which are targeted the angiogenic and 
oncogenic receptor tyrosine kinase (RTK). Regorafenib has been no-
ticed to affect the VEGFR2-TIE2 tyrosine kinase inhibition. Howev-
er, the molecular composition is like Sorafenib. Regorafenib is used 
with patients who have been treated with sorafenib before. Thus, it 
can be used to treat the advanced stage of HCC. The combination of 
Regorafenib and Nivolumab after Sorafenib treatment is still under 
experimentation and research is still underway to prove its validity in 
the treatment of phase III in HCC[56]. However, Figure 4 shown the 
treatment methods of HCC related to the stages. 
    Radioembolization is another option of treatment which intra-
arterial injection of microspheres is loaded with yttrium-90. The 90Y 
has a half-life 2.67 days and the ability of penetration into tissues 
between 2.5-11 mm. There are two types of 90Y available glass and 
resin microspheres and can attach to small beads. Moreover, the 90Y 
technique immunizing the post-embolization incident. However, this 
technique has many complications such as jaundice, sinusoidal ob-
struction syndrome, moderate cholestasis, and ascites. In summary, 
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increase the likelihood of tumors recurrence. The metastasis will take 
place through the vascular spread. Thus, the adjuvant therapy was 
advanced to improve the outcomes such as Lyso-thermosensitive 
liposomal doxorubicin (LTLD) due to quickly diffuses in the local 
tissues around the tumor cells by rapid heat released through the lipo-
somes[46]. LTLD locally releases a high concentration of doxorubicin. 
We aimed to determine whether adding LTLD improves the efficacy 
of radiofrequency ablation (RFA).
    The RS is one of the methods of curative treatment which repre-
sents an option for early-stage treatment in the patient who cannot 
do the liver ablation and LT. This method is more effective in a long 
term outcome more than 10 years comparing with RFA, LR and LT 
which have a 5 years period of treatment[47].
    The early diagnosis of HCC gives a good chance to provide the 
suitable treatment and improvement the survival. However, the tumor 
recurrence occurs in 30% from the patients treated by the curative 
treatment[48] randomized, open-label, phase 3 trial of the efficacy and 
safety of adjuvant immunotherapy with activated CIK cells (created 
by incubation of patients’ peripheral blood mononuclear cells with 
interleukin 2 and an antibody against CD3.
2. Intermediate stage 
Most patients who have history of cancer and are not candidates for 
treatment using resection or transplant, thus, the big categories for 
options of the patient is loco-regional therapy (LRT), which essen-
tially means therapy targeted to the liver. There are different types 
of LRT have been used, while the trans-arterial chemoembolization 
(TACE) is the most common[49].
    TACE is a minimally invasive procedure that uses many anti-
cancer agents. They include intra-arterial infusion of chemotherapy 
(usually cisplatin or doxorubicin) mixed with lipiodol and gelatin 
sponge particle which injects into liver tumors through a catheter to 
treat cancers. TACE used to treat asymptomatic patients and the in-
termediate stage of the HCC. The procedure involves the injection of 
chemotherapy filled microspheres inside the artery that feeds a tumor. 
A catheter is inserted into the femoral artery and advanced until it 
reaches to the common hepatic artery, once the catheter is accurately 
positioned an angiogram is performed to visualize the tumor. Micro-
spheres are injected into the catheter and released inside the feeder 
vessels, these microspheres slow blood flow as they travel and settle 
in the surface vessels and interior vessels of the tumor. Simultane-
ously, the microspheres start to controlled release of chemotherapy, 
this process is sustained over 14 days. Shrinkage and necrosis the 
tumor can be seen four to six weeks after the procedure[50,51] which 
elicits a sustained therapeutic response. DESIGN Time-of-flight mass 
cytometry and next-generation sequencing (NGS).
    Anti-angiogenesis treatments are the process of making the new 
blood vessels in a person with cancer, this process creates new blood 
vessels that give a tumor its own blood supply and allow it to grow. 
Anti-angiogenic drugs target against blood vessels that tumor needs 
to survive. Treatment can be given intravenously or oral, as the drugs 
travels through the body it targets specific molecules associated with 
the tumor is vessels. Anti-angiogenic drugs inhibit vessel growth and 
cause existing vessels to undergo a process of normalization. As the 
vessels normalize their numerous branches regress and straight re-
ducing blood supply to the tumor. Shrinkage and necrosis the tumor 
result the normalization process.
    Because Anti-angiogenic drugs and chemoembolization works 
differently, sometimes they can be given together. Tumor vessels 
normalized when given anti-angiogenic drugs, these normalized ves-
sels may provide a better route for microspheres to reach more of the 
the following paragraphs gives guideline and treatments option for 
HCC for all of the parameters needed for Child-Pugh stage, vascular 
invasion, HCC number and sizes.
    There are another treatment methods that can be used for specific 
inhibitors such as lenvatinib (inhibitor of VEGFR 1-3, PDGF, KIT, 
and RET), ramucirumab, tivantinib (inhibitor of c-Met positivity), 
and cabozantinib (inhibitor of VEGFR2, MET, and RET).
CONCLUSION
For the Conclusion, I have done some minor editing as follows: The 
present review summarized the current knowledge hepatocellular car-
cinoma, its molecular biology and risk factors, as well as the art in the 
diagnosis and treatment of the disease. However, detailed information 
about the HCC mechanism in the invasion of neighboring cells and 
metastasis are not yet fully understood. Future studies should focus 
on determining their mechanisms and identifying potential diagnostic 
and therapeutic strategies in HCC. The understanding of HCC will 
not improve by itself the efficiency of chemo or radiotherapy. A bet-
ter understanding of the disease could lead to a better choice of treat-
ment for each patient, or the development of more effective or safer 
treatment. Therefore, a deeper understanding of HCC might bring 
breakthroughs and transformative changes in the diagnosis and treat-
ment of HCC in the future.
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